Drug intelligence / Profile preview

KPL-045

Development stage: Discontinued
Lead developer: Kiniksa Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous (based On Typical Monoclonal Antibody Administration; Specific Routes Not Explicitly Stated But Iv And Sc Were Used In Related Antibodies)

Overview

KPL-045 is an investigational fully-human monoclonal antibody designed to inhibit the interaction between CD30 and its ligand CD30L, a T-cell co-stimulatory receptor involved in activating and sustaining memory T-cells. By blocking this interaction, it aims to modulate immune responses driven by activated T-memory cells. It was developed primarily for autoimmune and inflammatory diseases but was discontinued from clinical development based on preclinical data within the developer's portfolio. The drug was developed by Kiniksa Pharmaceuticals.

Other names: KPL 045KPL045KPL-045

Targets

TNFSF8 (CD30 ligand)CD30 (CD30 antigen)

Beyond the preview

Go deeper on KPL-045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KPL-045.